Melanoma

Dirk Schadendorf; Alexander C.J. van Akkooi; Carola Berking; Klaus Griewank; Ralf Gutzmer; Axel Hauschild; Andreas Stang; Alexander Roesch; Selma Ugurel

doi:10.1016/s0140-6736(18)31559-9

Keywords

MelanomaMedicineOncologyCancerTargeted therapyCancer researchDiseaseClinical trialKinaseMetastatic melanomaInternal medicineBiology

Affiliated Institutions

Related Publications

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long , Daniil Stroyakovskiy , Helen Gogas +32 more

A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic...

2014 New England Journal of Medicine 1791 citations

Pathways and therapeutic targets in melanoma

Emma Shtivelman , Michael A. Davies , Patrick Hwu +5 more

This review aims to summarize the current knowledge of molecular pathways and their clinical relevance in melanoma. Metastatic melanoma was a grim diagnosis, but in recent years...

2014 Oncotarget 213 citations

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimu...

2015 New England Journal of Medicine 7913 citations

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Caroline Robert , Jean‐Jacques Grob , Daniil Stroyakovskiy +23 more

First-line treatment with dabrafenib plus trametinib led to long-term benefit in approximately one third of the patients who had unresectable or metastatic melanoma with a <i>BR...

2019 New England Journal of Medicine 1283 citations

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon Bollag , Peter Hirth , James Tsai +37 more

B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that the...

2010 Nature 1800 citations

Publication Info

Year: 2018
Type: review
Volume: 392
Issue: 10151
Pages: 971-984
Citations: 1387
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Melanoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1387

OpenAlex

Cite This

APA Style

                            
                                
                                    Dirk Schadendorf, 
                                
                                    Alexander C.J. van Akkooi, 
                                
                                    Carola Berking
                                
                                et al.
                            
                            (2018). 
                            Melanoma. 
                            The Lancet
                            , 392
                            (10151)
                            , 971-984.
                            https://doi.org/10.1016/s0140-6736(18)31559-9
                        

Identifiers

DOI: 10.1016/s0140-6736(18)31559-9